{
    "eid": "2-s2.0-84921439608",
    "title": "Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia",
    "cover-date": "2015-02-01",
    "subject-areas": [
        {
            "$": "Geriatrics and Gerontology",
            "@code": "2717"
        },
        {
            "$": "Neurology",
            "@code": "2808"
        },
        {
            "$": "Neurology (clinical)",
            "@code": "2728"
        }
    ],
    "keywords": [
        "Botulinum toxin",
        "Cervical dystonia",
        "Secondary non-response"
    ],
    "authors": [
        "Joaquim J. Ferreira"
    ],
    "citedby-count": 27,
    "ref-count": 18,
    "ref-list": [
        "Epidemiology, clinical presentation, and diagnosis of cervical dystonia",
        "EFNS guidelines on diagnosis and treatment of primary dystonias",
        "Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol",
        "Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders",
        "Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: A systematic review",
        "Long-term efficacy and safety of botulinum toxin injections in dystonia",
        "Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?",
        "Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA",
        "Long-term follow-up of cervical dystonia patients treated with botulinum toxin A",
        "Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency",
        "Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period",
        "Survey of practices employed by neurologists for the definition and management of secondary nonresponse to botulinum toxin in cervical dystonia",
        "Guidelines for good pharmacoepidemiology practices (GPP)",
        "Immunogenicity of botulinum toxins",
        "Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia",
        "Treatment of complex cervical dystonia with botulinum toxin: Involvement of deep-cervical muscles may contribute to suboptimal responses",
        "Dystonia - the many facet",
        "Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: Results from an international observational study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rome",
            "affilname": "Faculty of Medicine and Psychology",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Cl\u00ednic de Barcelona",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Lisbon",
            "affilname": "Faculdade de Medicina da Universidade de Lisboa",
            "affiliation-country": "Portugal"
        },
        {
            "affiliation-city": "Boulogne-Billancourt",
            "affilname": "Ipsen",
            "affiliation-country": "France"
        }
    ],
    "funding": [
        "Funda\u00e7\u00e3o MSD",
        "Grunenthal",
        "Ipsen Pharma",
        "Merck-Serono and Merz",
        "Rachadaphiseksomphot Endowment Fund part of the \u201cStrengthen CUs",
        "GlaxoSmithKline",
        "Teva Pharmaceutical Industries",
        "Chulalongkorn University"
    ]
}